ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
133.163,60
0,12%
S&P 500
5.747,40
0,04%
US Dollar vs BRL
5,437
-0,02%
Bitcoin
66.045,13
1,32%
Brent Oil
71,455
0,71%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Aldeyra Therapeutics Inc (ALDX)

  7. Aldeyra Therapeutics Inc (ALDX) Notícias

ALDX

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALDX
DataHoraFonteTítuloCódigoCompanhia
10/09/202417:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
05/09/202408:00Business WireAldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
03/09/202410:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
14/08/202417:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
12/08/202419:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
08/08/202408:00Business WireAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
07/08/202417:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
01/08/202418:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALDXAldeyra Therapeutics Inc
01/08/202417:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
20/06/202408:00Business WireAldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableNASDAQ:ALDXAldeyra Therapeutics Inc
13/06/202408:00Business WireAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
12/06/202408:00Business WireAldeyra Therapeutics to Host Investor Roundtable Q&ANASDAQ:ALDXAldeyra Therapeutics Inc
29/05/202408:00Business WireAldeyra Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
08/05/202408:00Business WireAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
25/04/202408:00Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayNASDAQ:ALDXAldeyra Therapeutics Inc
18/04/202408:00Business WireAldeyra Therapeutics to Host Research & Development Day on April 25, 2024NASDAQ:ALDXAldeyra Therapeutics Inc
28/03/202408:00Business WireAldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:40Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALDXAldeyra Therapeutics Inc
06/02/202409:00Business WireAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
29/01/202419:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202409:00Business WireAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202309:00Business WireAldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
18/12/202318:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
27/11/202318:07Business WireAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
01/11/202308:05Business WireAldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
27/09/202306:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)NASDAQ:ALDXAldeyra Therapeutics Inc
11/08/202306:45PR Newswire (US)ALDX SHAREHOLDER ALERT: Jakubowitz Law Reminds Aldeyra Shareholders of a Lead Plaintiff Deadline of September 29, 2023NASDAQ:ALDXAldeyra Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALDX

Seu Histórico Recente

USOTC
PSSR
PASSUR Aerospace (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados